Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

CA64134N2032
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01GP1RJJ2
NURL
Neural Therapeutics Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Neural Therapeutics Inc.
ISIN
CA64134N2032
TICKER
NURL
MIC
XCNQ
REUTERS
NURL.CD
BLOOMBERG
NURL CN
Fri, 19.06.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions provided under Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Ventu...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce the results of its annual general and special meeting of shareholders held on May 25, 2026 (the "Meeting"), including shareholder approval of the acquisition by Neural of the remaining 69.25% equit...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.05.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, announces that it has filed on SEDAR+ and completed the mailing of its...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has entered into a second amending agreement (the "SIO Amendment") to its strategic investment and option agreement dated May 26, 2025, as previously amended (the "SIO Agreement"), with CWE European Ho...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Neural Therapeutics
CA64134N2032

VANCOUVER, BC, Feb. 19, 2026 /CNW/ - Trading resumes in: Company: Neural Therapeutics Inc.CSE Symbol: NURLAll Issues: YesResumption (ET): 11:30 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the nati...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - February 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has formally applied to the Canadian Securities Exchange (the "CSE") for approval to acquire the remaining 69.25% interest in CWE European Holdings Inc. ("CWE"), operating as Hanf.com,...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Neural Therapeutics
CA64134N2032

VANCOUVER, BC, Feb. 19, 2026 /CNW/ - The following issues have been halted by CIRO: Company: Neural Therapeutics Inc.CSE Symbol: NURL All Issues: YesReason: Pending News Halt Time (ET): 8:14 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ens...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Neural Therapeutics
CA64134N2032

Instrument ID [23290954] (HANF - CA64134N2032) suspended...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.02.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 27.01.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("C...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - November 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("C...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.10.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - October 8, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on therapeutic solutions for mental health conditions, together with its portfolio company CWE European Holdings Inc. ("CWE", operating as Hanf.com), one of Germany's l...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.09.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - September 23, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for substance use disorders, together with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CB...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.08.2025       Neural Therapeutics
CA64134N2032

Transaction transforms Neural into company with solid financial fundamentals with significant short, mid and long-term growth prospects Hanf.com achieved sales of €4.9 Million (~CA$7.5M) and a 13% operating profit in 20241. Toronto, Ontario--(Newsfile Corp. - August 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or th...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.07.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - July 22, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 21.07.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce two major developments that strengthen its ethnobotanical...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.06.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of the Germany'...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.05.2025       Neural Therapeutics
CA64134N2032

VANCOUVER, BC, May 28, 2025 /CNW/ - Trading resumes in: Company: Neural Therapeutics Inc. CSE Symbol: NURL All Issues: Yes Resumption (ET): 2:30 PM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.05.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, a leading Germ...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 28.05.2025       Neural Therapeutics
CA64134N2032

VANCOUVER, BC, May 28, 2025 /CNW/ - The following issues have been halted by CIRO: Company: Neural Therapeutics Inc. CSE Symbol: NURL All Issues: Yes Reason: Pending News Halt Time (ET): 9:24 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.05.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, announces that the Board of Directors approved the grant of 2,720,000 restricted s...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.05.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - May 9, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that it has submitted a renewal application to Servic...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.04.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - April 16, 2025) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for March 2025.March 2025 Operating StatisticsTrading volume of CSE listed securities totaled 1.1 billion shares;Trading value of CSE listed securities was $296 million;CSE issuers completed 85 financing...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.04.2025       Neural Therapeutics
CA64134N2032

Treatment of Major DSM-5 Disorders, Including Addiction, Depression and Anxiety, With Sub-Hallucinogenic Mescaline DosesExtraction Technology Delivering Higher Yields and Greater PurityFrankfurt Stock Exchange Ticker Symbol Changed to "HANF"Extension of LOI with CWE European Holdings (dba Hanf.com) Toronto, Ontario--(Newsfile Corp. - April 14, 2025...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 31.03.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - March 31, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: M6B) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that shares of the company have commenced trading on the...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.03.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - March 17, 2025) - he Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of Neural Therapeutics Inc. ("Neural Therapeutics" or the "Company"). The Toronto-based company has completed a private placement financing, and its common shares have been approved for listing on the CSE under...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.03.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - March 17, 2025) - Neural Therapeutics Inc. (CSE: NURL) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that its common shares will commence trading on the Canadian Securi...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.03.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - Le 13 mars/March 2025) - The common shares of Neural Therapeutics Inc. have been approved for listing on the CSE. Listing and disclosure documents will be available at www.thecse.com on the trading date. Neural Therapeutics is an ethnobotanical drug discovery company, focusing on the d...
Read more
Neural Therapeutics
Technical Analysis Termsheets Terminal
Permalink